ProShares Ultra Bloomberg Natural Gas

United States Natural Gas

MicroSectors Gold Miners 3X Leveraged ETN

Direxion Daily TSLA Bull 1.5X Shares

Direxion Daily Gold Miners Bull 3X ETF

ProShares Ultra Silver

GraniteShares 1.25x Long Tesla Daily ETF

Altimmune Inc. Common Stock

Direxion Daily FTSE China Bull 3X ETF

Global X Silver Miners ETF

ProShares UltraShort Bloomberg Natrl Gas

MicroSectors Gold Miners -3X Inverse Leveraged ETNs

T-REX 2X Inverse Tesla Daily Target ETF

Direxion Daily Gold Miners Bear 3X ETF

ProShares UltraShort Silver

Volatility Shares Trust 2x Ether ETF

iShares Ethereum Trust ETF

GraniteShares 2x Long AMZN Daily ETF

VS TR 2x Long VIX Futures ETF

Direxion Daily 20+ Yr Trsy Bull 3X ETF

BloomZ Inc. Ordinary Shares

Siyata Mobile Inc. Common Shares

Neuraxis Inc. Common Stock

TNL Mediagene Ordinary Shares

Edible Garden AG Incorporated Common Stock

Eyenovia Inc. Common Stock

D-Wave Quantum Inc. Common Shares

Click Holdings Limited Ordinary Share

Mind Medicine (MindMed) Inc. Common Shares

Pony AI Inc. American Depositary Shares

Protagenic Therapeutics Inc. Common Stock

NWTN Inc. Class B Ordinary Shares

ASP Isotopes Inc. Common Stock

New Fortress Energy Inc. Class A Common Stock

Hyperscale Data Inc. Common Stock

Canaan Inc. American Depositary Shares

Eagle Materials Inc Common Stock

Classover Holdings Inc. Class B Common Stock

MicroAlgo Inc. Ordinary Shares

Twin Vee PowerCats Co. Common Stock

Click here to get full coverage on First-Ever Phase 3 Trial Targets Both Forms of HCM: Lexicon's 500-Patient Global Study Could Transform Treatment - Stock Titan

First-Ever Phase 3 Trial Targets Both Forms of HCM: Lexicon's 500-Patient Global Study Could Transform Treatment  Stock Titan

First-Ever Phase 3 Trial Targets Both Forms of HCM: Lexicon's 500-Patient Global Study Could Transform Treatment - Stock Titan

Click here to get full coverage on Cytokinetics Announces SEQUOIA-HCM Analysis Results Highlighting Aficamten's Efficacy and Disparities in Hypertrophic Cardiomyopathy Outcomes Across Patient Demographics - Nasdaq

Cytokinetics Announces SEQUOIA-HCM Analysis Results Highlighting Aficamten's Efficacy and Disparities in Hypertrophic Cardiomyopathy Outcomes Across Patient Demographics  Nasdaq

Cytokinetics Announces SEQUOIA-HCM Analysis Results Highlighting Aficamten's Efficacy and Disparities in Hypertrophic Cardiomyopathy Outcomes Across Patient Demographics - Nasdaq

Click here to get full coverage on Fragmented HCM systems jeopardize business efficiency, Paycom research reveals - Yahoo Finance

Fragmented HCM systems jeopardize business efficiency, Paycom research reveals  Yahoo Finance

Fragmented HCM systems jeopardize business efficiency, Paycom research reveals - Yahoo Finance

Click here to get full coverage on Mavacamten Strikes Out in Phase III Trial of Nonobstructive HCM - TCTMD.com

Mavacamten Strikes Out in Phase III Trial of Nonobstructive HCM  TCTMD.com

Mavacamten Strikes Out in Phase III Trial of Nonobstructive HCM - TCTMD.com

Click here to get full coverage on HCM City secures US$6 bln deal for green energy, oil refinery projects - vietnamnews.vn

HCM City secures US$6 bln deal for green energy, oil refinery projects  vietnamnews.vn

HCM City secures US$6 bln deal for green energy, oil refinery projects - vietnamnews.vn

Click here to get full coverage on Cytokinetics Announces Positive Topline Results From MAPLE-HCM - GlobeNewswire

Cytokinetics Announces Positive Topline Results From MAPLE-HCM  GlobeNewswire

Cytokinetics Announces Positive Topline Results From MAPLE-HCM - GlobeNewswire

Click here to get full coverage on FDA Approved NDA for Aficamten to Treat Patients With Obstructive Hypertrophic Cardiomyopathy - Pharmacy Times

FDA Approved NDA for Aficamten to Treat Patients With Obstructive Hypertrophic Cardiomyopathy  Pharmacy Times

FDA Approved NDA for Aficamten to Treat Patients With Obstructive Hypertrophic Cardiomyopathy - Pharmacy Times

Click here to get full coverage on Peoplesoft HCM to be unavailable early Sunday - The Daily | Case Western Reserve University

Peoplesoft HCM to be unavailable early Sunday  The Daily | Case Western Reserve University

Peoplesoft HCM to be unavailable early Sunday - The Daily | Case Western Reserve University

Click here to get full coverage on Tenaya highlights HCM gene therapy interim data at ACC 2025 - Clinical Trials Arena

Tenaya highlights HCM gene therapy interim data at ACC 2025  Clinical Trials Arena

Tenaya highlights HCM gene therapy interim data at ACC 2025 - Clinical Trials Arena

Click here to get full coverage on Broken hearts mended? Rapamycin shows promise preventing feline HCM pathology - AAHA

Broken hearts mended? Rapamycin shows promise preventing feline HCM pathology  AAHA

Broken hearts mended? Rapamycin shows promise preventing feline HCM pathology - AAHA

Click here to get full coverage on First drug shown to reverse feline HCM expected to receive FDA conditional approval - DVM360

First drug shown to reverse feline HCM expected to receive FDA conditional approval  DVM360

First drug shown to reverse feline HCM expected to receive FDA conditional approval - DVM360

Click here to get full coverage on What to Expect From a Heart Transplant for Hypertrophic Cardiomyopathy - HealthCentral

What to Expect From a Heart Transplant for Hypertrophic Cardiomyopathy  HealthCentral

What to Expect From a Heart Transplant for Hypertrophic Cardiomyopathy - HealthCentral

Click here to get full coverage on Jefferson County group aims to help prevent cardiac arrest in young athletes - WBMA

Jefferson County group aims to help prevent cardiac arrest in young athletes  WBMA

Jefferson County group aims to help prevent cardiac arrest in young athletes - WBMA

Click here to get full coverage on Human Capital Management (HCM) Market Expected to Hit USD 43.1 - openPR.com

Human Capital Management (HCM) Market Expected to Hit USD 43.1  openPR.com

Human Capital Management (HCM) Market Expected to Hit USD 43.1 - openPR.com

Click here to get full coverage on Cytokinetics (CYTK) Showcases Promising Aficamten Data for HCM Treatment | CYTK Stock News - GuruFocus

Cytokinetics (CYTK) Showcases Promising Aficamten Data for HCM Treatment | CYTK Stock News  GuruFocus

Cytokinetics (CYTK) Showcases Promising Aficamten Data for HCM Treatment | CYTK Stock News - GuruFocus

Click here to get full coverage on Protein interactions, network pharmacology, and machine learning work together to predict genes linked to mitochondrial dysfunction in hypertrophic cardiomyopathy - Nature

Protein interactions, network pharmacology, and machine learning work together to predict genes linked to mitochondrial dysfunction in hypertrophic cardiomyopathy  Nature

Protein interactions, network pharmacology, and machine learning work together to predict genes linked to mitochondrial dysfunction in hypertrophic cardiomyopathy - Nature

Click here to get full coverage on Clinical Trial Success: Aficamten Delivers Consistent Results Across All HCM Patient Groups in Global Study - Stock Titan

Clinical Trial Success: Aficamten Delivers Consistent Results Across All HCM Patient Groups in Global Study  Stock Titan

Clinical Trial Success: Aficamten Delivers Consistent Results Across All HCM Patient Groups in Global Study - Stock Titan

Click here to get full coverage on Cytokinetics Announces Launch of EARTH-HCM, a Public Health - GlobeNewswire

Cytokinetics Announces Launch of EARTH-HCM, a Public Health  GlobeNewswire

Cytokinetics Announces Launch of EARTH-HCM, a Public Health - GlobeNewswire

Click here to get full coverage on Human Capital Management - CBIZ

Human Capital Management - CBIZ

Click here to get full coverage on Evaluation of polygenic scores for hypertrophic cardiomyopathy in the general population and across clinical settings - Nature

Evaluation of polygenic scores for hypertrophic cardiomyopathy in the general population and across clinical settings  Nature

Evaluation of polygenic scores for hypertrophic cardiomyopathy in the general population and across clinical settings - Nature

Click here to get full coverage on Oracle AI Agents Help HR Leaders Reshape the Employee Experience - Oracle

Oracle AI Agents Help HR Leaders Reshape the Employee Experience  Oracle

Oracle AI Agents Help HR Leaders Reshape the Employee Experience - Oracle

Click here to get full coverage on Large-scale genome-wide association analyses identify novel genetic loci and mechanisms in hypertrophic cardiomyopathy - Nature

Large-scale genome-wide association analyses identify novel genetic loci and mechanisms in hypertrophic cardiomyopathy  Nature

Large-scale genome-wide association analyses identify novel genetic loci and mechanisms in hypertrophic cardiomyopathy - Nature

Click here to get full coverage on What Causes Hypertrophic Cardiomyopathy? - Verywell Health

What Causes Hypertrophic Cardiomyopathy?  Verywell Health

What Causes Hypertrophic Cardiomyopathy? - Verywell Health

Click here to get full coverage on Patient story: Early diagnosis counts — How Johan discovered his HCM in time - Bristol Myers Squibb

Patient story: Early diagnosis counts — How Johan discovered his HCM in time  Bristol Myers Squibb

Patient story: Early diagnosis counts — How Johan discovered his HCM in time - Bristol Myers Squibb

Click here to get full coverage on Doctor-Approved Tips for Caring for Yourself With HCM - HealthCentral

Doctor-Approved Tips for Caring for Yourself With HCM  HealthCentral

Doctor-Approved Tips for Caring for Yourself With HCM - HealthCentral

Click here to get full coverage on Cytokinetics shares positive phase 3 results for aficamten in heart disease - PMLiVE

Cytokinetics shares positive phase 3 results for aficamten in heart disease  PMLiVE

Cytokinetics shares positive phase 3 results for aficamten in heart disease - PMLiVE

Click here to get full coverage on Safety signals overshadow Edgewise's HCM drug trial results - FirstWord Pharma

Safety signals overshadow Edgewise's HCM drug trial results  FirstWord Pharma

Safety signals overshadow Edgewise's HCM drug trial results - FirstWord Pharma

Click here to get full coverage on BMS's Camzyos falls short in Phase III non-obstructive HCM trial - FirstWord Pharma

BMS's Camzyos falls short in Phase III non-obstructive HCM trial  FirstWord Pharma

BMS's Camzyos falls short in Phase III non-obstructive HCM trial - FirstWord Pharma

Click here to get full coverage on Abstract 4132223: Mavacamten in adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy: design of the Phase 3 SCOUT-HCM trial - American Heart Association Journals

Abstract 4132223: Mavacamten in adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy: design of the Phase 3 SCOUT-HCM trial  American Heart Association Journals

Abstract 4132223: Mavacamten in adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy: design of the Phase 3 SCOUT-HCM trial - American Heart Association Journals

Click here to get full coverage on AI-Enhanced ECG Analysis Shows Strong Accuracy in Detecting Hypertrophic Cardiomyopathy - Cleveland Clinic

AI-Enhanced ECG Analysis Shows Strong Accuracy in Detecting Hypertrophic Cardiomyopathy  Cleveland Clinic

AI-Enhanced ECG Analysis Shows Strong Accuracy in Detecting Hypertrophic Cardiomyopathy - Cleveland Clinic

Click here to get full coverage on Aficamten Shows Promise Over Metoprolol in Phase 3 MAPLE-HCM Trial for Obstructive HCM - Medical Dialogues

Aficamten Shows Promise Over Metoprolol in Phase 3 MAPLE-HCM Trial for Obstructive HCM  Medical Dialogues

Aficamten Shows Promise Over Metoprolol in Phase 3 MAPLE-HCM Trial for Obstructive HCM - Medical Dialogues

Click here to get full coverage on Hypertrophic Cardiomyopathy Awareness Day Is February 26 - Healthline

Hypertrophic Cardiomyopathy Awareness Day Is February 26  Healthline

Hypertrophic Cardiomyopathy Awareness Day Is February 26 - Healthline

Click here to get full coverage on How Hypertrophic Cardiomyopathy Is Diagnosed - Time Magazine

How Hypertrophic Cardiomyopathy Is Diagnosed  Time Magazine

How Hypertrophic Cardiomyopathy Is Diagnosed - Time Magazine

Click here to get full coverage on HealthCentral: Can a Blood Test Diagnose Hypertrophic Cardiomyopathy? - Cedars-Sinai

HealthCentral: Can a Blood Test Diagnose Hypertrophic Cardiomyopathy?  Cedars-Sinai

HealthCentral: Can a Blood Test Diagnose Hypertrophic Cardiomyopathy? - Cedars-Sinai

Click here to get full coverage on Mavacamten Still Effective for Hypertrophic Cardiomyopathy - Cleveland Clinic

Mavacamten Still Effective for Hypertrophic Cardiomyopathy  Cleveland Clinic

Mavacamten Still Effective for Hypertrophic Cardiomyopathy - Cleveland Clinic

Click here to get full coverage on Serial Changes in Ventricular Strain in Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Insights From the VALOR-HCM Trial - American Heart Association Journals

Serial Changes in Ventricular Strain in Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Insights From the VALOR-HCM Trial  American Heart Association Journals

Serial Changes in Ventricular Strain in Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Insights From the VALOR-HCM Trial - American Heart Association Journals

Click here to get full coverage on Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) - PR Newswire

Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM)  PR Newswire

Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) - PR Newswire

Click here to get full coverage on Oracle Named a Leader in Gartner® Magic Quadrant™ for Cloud HCM Suites for 1,000+ Employee Enterprises for Ninth Consecutive Year - Oracle

Oracle Named a Leader in Gartner® Magic Quadrant™ for Cloud HCM Suites for 1,000+ Employee Enterprises for Ninth Consecutive Year  Oracle

Oracle Named a Leader in Gartner® Magic Quadrant™ for Cloud HCM Suites for 1,000+ Employee Enterprises for Ninth Consecutive Year - Oracle

Click here to get full coverage on ADP Named Market Leader for HCM Suites 2025 by ISG Research - ADP

ADP Named Market Leader for HCM Suites 2025 by ISG Research  ADP

ADP Named Market Leader for HCM Suites 2025 by ISG Research - ADP

Click here to get full coverage on G&A Partners Expands HCM Reach with Acquisition of AmCheck Austin and Las Vegas - Business Wire

G&A Partners Expands HCM Reach with Acquisition of AmCheck Austin and Las Vegas  Business Wire

G&A Partners Expands HCM Reach with Acquisition of AmCheck Austin and Las Vegas - Business Wire

Click here to get full coverage on Aficamten and Cardiac Remodeling in FOREST-HCM, with Ahmad Masri, MD, MS - HCPLive

Aficamten and Cardiac Remodeling in FOREST-HCM, with Ahmad Masri, MD, MS  HCPLive

Aficamten and Cardiac Remodeling in FOREST-HCM, with Ahmad Masri, MD, MS - HCPLive

Click here to get full coverage on Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress - The Manila Times

Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress  The Manila Times

Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress - The Manila Times

Click here to get full coverage on Can a Blood Test Diagnose Hypertrophic Cardiomyopathy? - HealthCentral

Can a Blood Test Diagnose Hypertrophic Cardiomyopathy?  HealthCentral

Can a Blood Test Diagnose Hypertrophic Cardiomyopathy? - HealthCentral

Click here to get full coverage on Abstract 4143175: Real-world Long-term Effectiveness of Mavacamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: a Multicenter Observational Study (MARVEL-HCM) - American Heart Association Journals

Abstract 4143175: Real-world Long-term Effectiveness of Mavacamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: a Multicenter Observational Study (MARVEL-HCM)  American Heart Association Journals

Abstract 4143175: Real-world Long-term Effectiveness of Mavacamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: a Multicenter Observational Study (MARVEL-HCM) - American Heart Association Journals

Click here to get full coverage on Man loses wife and son to same heart condition: ‘I feel robbed’ - The Independent

Man loses wife and son to same heart condition: ‘I feel robbed’  The Independent

Man loses wife and son to same heart condition: ‘I feel robbed’ - The Independent

Click here to get full coverage on Claritev Provides Oracle Cloud HCM Customers with Actionable Insights for Healthcare Cost Optimization and Plan Design - Business Wire

Claritev Provides Oracle Cloud HCM Customers with Actionable Insights for Healthcare Cost Optimization and Plan Design  Business Wire

Claritev Provides Oracle Cloud HCM Customers with Actionable Insights for Healthcare Cost Optimization and Plan Design - Business Wire

Click here to get full coverage on PeopleSoft HCM to be unavailable tonight through tomorrow afternoon - The Daily | Case Western Reserve University

PeopleSoft HCM to be unavailable tonight through tomorrow afternoon  The Daily | Case Western Reserve University

PeopleSoft HCM to be unavailable tonight through tomorrow afternoon - The Daily | Case Western Reserve University

Click here to get full coverage on Viz.ai Receives Edison Award for HCM Module - Diagnostic and Interventional Cardiology

Viz.ai Receives Edison Award for HCM Module  Diagnostic and Interventional Cardiology

Viz.ai Receives Edison Award for HCM Module - Diagnostic and Interventional Cardiology

Click here to get full coverage on Long-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE Registry - American Heart Association Journals

Long-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE Registry  American Heart Association Journals

Long-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE Registry - American Heart Association Journals

Click here to get full coverage on ADP Celebrates 2025 HCM Distinction Award Winners at 40th Annual ADP® Meeting of the Minds Conference - PR Newswire

ADP Celebrates 2025 HCM Distinction Award Winners at 40th Annual ADP® Meeting of the Minds Conference  PR Newswire

ADP Celebrates 2025 HCM Distinction Award Winners at 40th Annual ADP® Meeting of the Minds Conference - PR Newswire

Click here to get full coverage on Intelligent HCM - Paycor

Intelligent HCM - Paycor

Click here to get full coverage on ADP Lyric HCM, The Next-Gen HR Platform Many Have Waited For - Josh Bersin

ADP Lyric HCM, The Next-Gen HR Platform Many Have Waited For  Josh Bersin

ADP Lyric HCM, The Next-Gen HR Platform Many Have Waited For - Josh Bersin

Click here to get full coverage on Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy - American Heart Association Journals

Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy  American Heart Association Journals

Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy - American Heart Association Journals

Click here to get full coverage on E.ON Moves Global HR Operations to Oracle Fusion Cloud HCM - Oracle

E.ON Moves Global HR Operations to Oracle Fusion Cloud HCM  Oracle

E.ON Moves Global HR Operations to Oracle Fusion Cloud HCM - Oracle

Click here to get full coverage on HR or Payroll: In Global HCM Transformation, What's the Best Order of Implementation? | SPARK Blog - ADP

HR or Payroll: In Global HCM Transformation, What's the Best Order of Implementation? | SPARK Blog  ADP

HUTCHMED DRC (HCM)

Price Chart

Key Statistics

Technicals

About HCM

Latest News

First-Ever Phase 3 Trial Targets Both Forms of HCM: Lexicon's 500-Patient Global Study Could Transform Treatment - Stock Titan

Cytokinetics Announces SEQUOIA-HCM Analysis Results Highlighting Aficamten's Efficacy and Disparities in Hypertrophic Cardiomyopathy Outcomes Across Patient Demographics - Nasdaq

Fragmented HCM systems jeopardize business efficiency, Paycom research reveals - Yahoo Finance

Advanced Charts

Top Gainers

Top Losers